This Research Topic is the second volume of the 'Community Series in Novel Antipsychotics Within and Beyond Clinical Trials: Symptom Based Treatment of Overlapping Psychiatric Disorders with D3-D2 Partial Agonists. Please see the first volume
here.
Novel, third-generation antipsychotic medications, such as cariprazine, have a unique mechanism of action characterized by D3-D2 partial agonism. Over the past few years, several papers have been published detailing the efficacy and safety of such medications in different psychiatric disorders including schizophrenia, mania, and bipolar depression based on the results of phase II and III clinical trials. While such data is vital, it is high time to explore the characteristics of novel antipsychotics further: not just within, but beyond the scope of clinical trials. Given that the ultimate goal of modern psychiatry is to provide the right treatment to the right patient at the right time, also called as personalized medicine, it is necessary to address psychiatric treatment from a different angle. Thus, the aim of this Research Topic is to increase the understanding on the role of D3-D2 partial agonists - both theoretically and based on clinical trial data and real-world evidence – regarding the treatment of different symptom domains and safety issues in overlapping psychiatric disorders.
This Research Topic welcomes any type of manuscripts from original research, reviews, systematic reviews and meta-analyses to case reports, and opinion papers in the following topics:
• Overlapping symptoms and safety issues in psychiatric disorders
• The effectiveness of D3-D2 dopamine partial agonists in the treatment of different symptom domains
• Addressing safety and tolerability issues with D3-D2 partial agonists in psychiatric disorders
Dr. György Németh and Zsófia Dombi are employees of Gedeon Richter Plc. Dr. Andrew Cutler serves as a Consultant and Promotional Honoraria (AbbVie (Allergan) Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Gedeon Richter, Indorsia, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Jazz Pharmaceuticals, Karuna, Lundbeck, Luye Pharma, Neumora (BlackThorn), Neurocrine, Noven, Otsuka, Relmada, Reviva Pharmaceuticals, Sage Therapeutics, Sunovion, Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics), member of the Data Safety Monitoring Board (COMPASS Pathways) and Board Member (Neuroscience Education Institute). The other Topic Editors declare no competing interests with regard to the Research Topic subject.This Research Topic is the second volume of the 'Community Series in Novel Antipsychotics Within and Beyond Clinical Trials: Symptom Based Treatment of Overlapping Psychiatric Disorders with D3-D2 Partial Agonists. Please see the first volume
here.
Novel, third-generation antipsychotic medications, such as cariprazine, have a unique mechanism of action characterized by D3-D2 partial agonism. Over the past few years, several papers have been published detailing the efficacy and safety of such medications in different psychiatric disorders including schizophrenia, mania, and bipolar depression based on the results of phase II and III clinical trials. While such data is vital, it is high time to explore the characteristics of novel antipsychotics further: not just within, but beyond the scope of clinical trials. Given that the ultimate goal of modern psychiatry is to provide the right treatment to the right patient at the right time, also called as personalized medicine, it is necessary to address psychiatric treatment from a different angle. Thus, the aim of this Research Topic is to increase the understanding on the role of D3-D2 partial agonists - both theoretically and based on clinical trial data and real-world evidence – regarding the treatment of different symptom domains and safety issues in overlapping psychiatric disorders.
This Research Topic welcomes any type of manuscripts from original research, reviews, systematic reviews and meta-analyses to case reports, and opinion papers in the following topics:
• Overlapping symptoms and safety issues in psychiatric disorders
• The effectiveness of D3-D2 dopamine partial agonists in the treatment of different symptom domains
• Addressing safety and tolerability issues with D3-D2 partial agonists in psychiatric disorders
Dr. György Németh and Zsófia Dombi are employees of Gedeon Richter Plc. Dr. Andrew Cutler serves as a Consultant and Promotional Honoraria (AbbVie (Allergan) Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Gedeon Richter, Indorsia, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Jazz Pharmaceuticals, Karuna, Lundbeck, Luye Pharma, Neumora (BlackThorn), Neurocrine, Noven, Otsuka, Relmada, Reviva Pharmaceuticals, Sage Therapeutics, Sunovion, Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics), member of the Data Safety Monitoring Board (COMPASS Pathways) and Board Member (Neuroscience Education Institute). The other Topic Editors declare no competing interests with regard to the Research Topic subject.